https://www.thepharmaletter.com/article/takeda-oncology-pipeline-shifts-in-focus
Takeda oncology pipeline shifts in focus
23-02-2024
Japan’s largest drugmaker Takeda (TYO: 4502) decided to discontinue the development programs of its
four oncology assets - Phase III asset modakafusp alfa (TAK-573) and three Phase I chimeric antigen
receptor (CAR-T) assets: TAK-102, TAK-103 and TAK-940 - as part of a plan to align its focus on advancing
allogeneic cell therapies.
Cell Therapy News/Articles, page-17512
-
- There are more pages in this discussion • 309 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |